Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCC in R/M HNSCC After Pembrolizumab Failure (CARPACCIO)
NCT06725368Phase 2Recruiting
- Sponsor
- Centre Paul Strauss
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, Paclitaxel Micelles for Injection, carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Centre Paul Strauss. Started Jan 2025; status: recruiting.
02
Drugs
KL-140Paclitaxel Micelles for Injectioncarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06725368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06725368.